氨溴索对体外循环心内直视术后呼吸道并发症的影响  

Effects of Ambroxol on Pespiratory Complications after Heart Operation under Cardiopulmonary Bypass

作　　者：孙鹏飞[1] 史举彤[1] 韩珂[1] 魏振宇[1] 

机构地区：[1]青岛大学医学院附属烟台毓璜顶医院,山东烟台264000

出　　处：《临床误诊误治》2007年第11期3-5,共3页Clinical Misdiagnosis & Mistherapy

摘　　要：目的：观察氨溴索（沐舒坦）对减少心内直视术后呼吸道并发症的作用。方法：将100例心内直视术后患者，随机分为氨溴索治疗组（治疗组）和溴己新对照组（对照组），每组各50例。两组均为术后2～14天用药，观察比较两组术后咳嗽程度、痰液黏稠度、排痰难度、肺部啰音、呼吸系统并发症及不良反应。结果：氨溴索治疗组痰液黏稠度、排痰难度、肺部哆音、肺不张发生率（治疗组为4％，对照组为14％）与溴己新对照组比较差异均具有显著统计学意义（P〈0．05）；两组均未见明显不良反应。结论：心内直视术后应用氨溴索可显著减少呼吸道并发症，尤其是肺不张的发生率。Objective：To observe the effects of ambroxol （Mucosolvan） on reducing respiratory complications after heart operations under cardiopulmonary bypass. Methods：One hundred patients were randomly divided into the ambroxol group （studied gruop） and Bikeping group （control group）. Each group consisted of fifty patients. 2 - 14d after treatment, density of phlegm,difficulty in expectoration, pneumonic rales, respiratory complications and side effects of drugs were observed and compared. Results ： The prevalence of high density of phlegm,difficulty in expectoration and pneumonic rales were markedly less in the studied group than in the control （P 〈0.05） . The prevalence of atelectasis in the studied group was 4% ,much lower than that in the control group 14 % （P 〈 0.05） . No obvious side effects were found in the two groups. Conclusion ： Administration of ambroxol in patients after heart operations under cardiopulmonary bypass can reduce the respiratory complications,especially atelectasis.

关 键 词：氨溴索 体外循环 心脏外科手术 肺功能 影响 

分 类 号：R654.2[医药卫生—外科学] R56[医药卫生—临床医学]